Best CDMOs in India — Ranked by Signal Score · 2026
· updated as new inspection, certificate, and trial data enters the platform
42
CDMOs in region
11
Fully scored
7
With FDA records
22
FDA inspections
21
EMA/MHRA GMP certs
CDMO Signal tracks 42 biopharma CDMOs with confirmed India manufacturing facilities, of which 11 are fully scored across the four-pillar composite Signal Score. Across all modalities, Piramal Pharma Solutions, Syngene International, and Simtra BioPharma Solutions lead the India ranking by composite score. Signal Score integrates FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. For modality-specific rankings within India — AAV, cell therapy, biologics, and 10 other tracked modalities — see the modality-region breakdown below. Full methodology at cdmosignal.com/methodology.
India-based CDMOs ranked by CDMO Signal's composite Signal Score, filtered to manufacturers with confirmed Indian facilities. India is one of the top three global CDMO manufacturing countries by volume, spanning oral solids, biologics, sterile injectables, and increasingly advanced-therapy platforms. Indian CDMOs range from domestic-market-focused to fully global with FDA + EMA + MHRA cross-jurisdictional certification. The ranking includes any CDMO with an Indian manufacturing site — filtering is derived from each CDMO's declared facility locations.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
PR
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
|
83.6 | 95.7 | 5 insp · 13 GMP | — | 0 programs |
| 2 |
SG
Syngene International
Bengaluru, India
|
79.7 | 95.9 | 2 insp · 0 GMP | — | 0 programs |
| 3 |
SI
Simtra BioPharma Solutions
Bloomington, IN · Halle, DE
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 4 |
BC
Biocon Biologics
Bangalore, India
|
77.1 | 96.1 | 4 insp · 2 GMP | — | 0 programs |
| 5 |
IP
Intas Pharmaceuticals
Ahmedabad, India
|
76.8 | 100.0 | 0 insp · 5 GMP | — | 0 programs |
| 6 |
GZ
Genezen
Indianapolis, IN · Lexington, MA
|
70.7 | 84.1 | 3 insp · 0 GMP | Available | 0 programs |
| 7 |
IU
Indiana University Vector Production Facility
Indianapolis, IN
|
66.2 | — | — | — | 49 programs |
| 8 |
AU
Aurigene Pharmaceutical Services
Hyderabad, India
|
63.0 | — | — | — | 0 programs |
| 9 |
SS
Singota Solutions
Bloomington, IN
|
59.0 | — | — | — | 0 programs |
| 10 |
CLB
Clara Biotech
Indianapolis, IN
|
56.5 | — | — | — | 0 programs |
| 11 |
IC
INCOG BioPharma Services
Fishers, IN
|
56.5 | — | — | — | 0 programs |
| — |
Sparsha Pharma International
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Zydus Lifesciences (Transdermal Mfg)
Ahmedabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Sun Pharmaceutical Industries Ltd.
Mumbai, India
|
Profiled | — | 5 insp · 0 GMP | — | 0 programs |
| — |
Biological E. Limited (BioE)
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Kemwell Biopharma
Bengaluru, India
|
Profiled | — | — | — | 0 programs |
| — |
Sai Life Sciences
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Aurobindo Pharma (Sterile Injectables Division)
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Kemwell Biopharma, Bangalore
Bengaluru, India
|
Profiled | — | — | — | 0 programs |
| — |
BE Biosol (formerly SGI Pharma / Biological E, Samirpet)
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Torrent Pharmaceuticals Limited
Ahmedabad, India
|
Profiled | — | 2 insp · 0 GMP | — | 0 programs |
| — |
Exelead (now MilliporeSigma / Merck KGaA — Indianapolis LNP Site)
Indianapolis, IN
|
Profiled | — | — | — | 0 programs |
| — |
Eli Lilly (Internal Manufacturing — Lebanon, IN)
Indianapolis, IN
|
Profiled | — | — | — | 0 programs |
| — |
Coral Drugs Private Limited
New Delhi, India
|
Profiled | — | — | — | 0 programs |
| — |
Aarti Pharmalabs Limited
Mumbai, India
|
Profiled | — | — | — | 0 programs |
| — |
Laurus Labs
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Optimus Pharma (Optimus Drugs Private Limited)
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Gland Pharma Limited
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Dr. Reddy's Laboratories
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Enzene Biosciences
Pune, India
|
Profiled | — | — | — | 0 programs |
| — |
Akums Drugs & Pharmaceuticals
Haridwar, India
|
Profiled | — | — | — | 0 programs |
| — |
Anthem Biosciences
Bengaluru, India
|
Profiled | — | 1 insp · 0 GMP | — | 0 programs |
| — |
FDC Limited
Mumbai, India
|
Profiled | — | — | — | 0 programs |
| — |
Apitoria Pharma Private Limited
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Maiva Pharma Pvt Ltd
Hosur, India
|
Profiled | — | — | — | 0 programs |
| — |
Cipla Limited
Mumbai, India
|
Profiled | — | — | — | 0 programs |
| — |
La Chandra Pharmalab Pvt Ltd
Ahmedabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Supreme Drugs Pvt Ltd
Palanpur, Gujarat, India
|
Profiled | — | — | — | 0 programs |
| — |
Jyot Pharmachem
Ankleshwar, Gujarat, India
|
Profiled | — | — | — | 0 programs |
| — |
VerGo Pharma Research Laboratories Pvt. Ltd.
Verna, Goa, India
|
Profiled | — | — | — | 0 programs |
| — |
Kodo LifeScience Pvt. Ltd.
Valsad, Gujarat, India
|
Profiled | — | — | — | 0 programs |
| — |
Kodo Lifescience Private Limited
Vapi/Valsad, India
|
Profiled | — | — | — | 0 programs |
How do Indian CDMOs compare to Chinese and Korean alternatives on regulatory posture?
Indian CDMOs have historically led Asian peers in FDA inspection density — the FDA maintains a large inspection presence in India and Indian pharmaceutical exports to the US are among the highest globally. That translates to Indian CDMOs typically holding more FDA inspections on record than Chinese or Korean counterparts of comparable size. That said, inspection density is not the same as inspection outcome — the Signal Score's Quality Compliance pillar weights the classification (NAI/VAI/OAI), not just the count. Sponsors comparing Asian CDMOs should focus on the specific facility's inspection outcome record, not the country-aggregate; individual profile pages surface facility-level detail.
Which Indian CDMOs handle biologics and advanced therapy modalities?
India's CDMO base has traditionally been strongest in small molecules and oral solid dosage forms, but the biologics and advanced-therapy footprint has grown substantially. Notable capabilities exist across mAb manufacturing, biosimilar production, and increasingly viral vector + cell therapy. Cross-reference with modality pages to filter Indian CDMOs by capability class: biologics, mRNA, cell therapy, or the gene therapy umbrella. Individual CDMO profile pages surface the specific modality capabilities on file.
US and EU regulatory considerations for India-manufactured drug supply
Indian CDMOs supplying US markets need active FDA registrations and pre-approval inspection posture; the FDA has been publicly focused on Indian generic pharmaceutical quality for years, and inspection outcomes there materially affect commercial supply eligibility. EU supply requires EMA GMP certification with an EU-based Qualified Person for batch release, which for Indian-manufactured material requires either an EU-based CDMO partner for release or an in-house EU QP arrangement. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so Indian CDMOs with cross-jurisdictional posture rank higher on this pillar than domestic-market-only competitors.
Browse by modality within India
Modality-specific rankings for India-manufactured programs. Each page filters the modality's global ranking to CDMOs with confirmed India facilities.
AAV / Gene Therapy (2)
CAR-T (1)
Lentiviral Vector (4)
Cell Therapy (6)
mRNA / LNP (2)
Plasmid DNA (2)
Biologics / mAb (15)
Oligonucleotide / ASO (5)
Exosome / Extracellular Vesicle (1)
Recombinant Proteins (5)
ADC (Antibody-Drug Conjugate) (9)
Gene Therapy (5)
Cell & Gene Therapy (11)
Viral Vector (4)